Microvasculature of tumor tissue

The microvasculature of tumor tissue refers to the network of small blood vessels within solid tumors. Unlike normal tissue vasculature, these vessels are structurally abnormal—characterized by irregular branching, tortuosity, leakiness, poor pericyte coverage, and disrupted basement membranes. This leads to heterogeneous blood flow, regions of hypoxia within the tumor mass, impaired immune cell infiltration due to physical barriers and altered adhesion molecule expression on endothelium, as well as inefficient delivery of chemotherapeutic agents[1][2][3]. The abnormal structure is driven by an imbalance between proangiogenic factors such as VEGF-A and antiangiogenic signals. Therapeutically targeting the tumor microvasculature has been a major strategy in oncology for decades; approaches include inhibiting new vessel formation ("antiangiogenesis") or attempting "vascular normalization"—restoring more normal vessel structure/function—to enhance treatment efficacy[3][4]. However, this is not a single molecular target but rather a complex multicellular system; thus it does not fit standard molecular classification schemes. Because "microvasculature of tumor tissue" describes an anatomical/functional feature rather than a discrete protein or receptor target—and encompasses multiple cellular/molecular components—it is considered an imprecise therapeutic target name for structured databases. “Tumour blood vessels are structurally abnormal and functionally anergic which limits drug access and immune responses in solid cancers. Thus tumour vasculature has been considered an attractive therapeutic target for decades.” [3]

Other names

Tumor vasculatureTumor microvasculatureTumor blood vesselsTumor microcirculation

Inhibition of angiogenesis by targeting vascular endothelial growth factor signaling or other proangiogenic pathways[3][4] Disruption or normalization of abnormal tumor blood vessels to improve perfusion and drug delivery[3][5]